profit from every PLN 100 of sales.
Mercator Medical
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2021 to 2023.
It has no yearly profit to compare the price with.
It holds more cash than debt.
Money in, money out
What Mercator Medical sold, what it kept, and what it did with the cash.
Sales went from PLN 1.73 billion in 2021 to PLN 469 million in 2023, with -PLN 19.7 million of profit last year.
Mercator Medical vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from PLN 100 of sales | Sales growth a year | Price per PLN 1 of profit |
|---|---|---|---|
| Mercator Medical | No profit yet | ||
Intuitive Surgical | 54.6× · Expensive | ||
EssilorLuxottica Société anonyme | 37.1× · Expensive | ||
Becton, Dickinson and | 34.5× · Expensive | ||
Medline | 46.5× · Expensive |
AI analysis
An AI analyst reads Mercator Medical's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of PLN | 2021 | 2022 | 2023 |
|---|---|---|---|
| 1,727 | 543 | 469 | |
| 684 | 88 | 79 | |
| 515 | -73 | -94 | |
| 497 | -160 | 19 | |
| 447 | -190 | -20 | |
| 44.15 | -19.41 | -2.05 | |
| 39.6% | 16.3% | 16.9% | |
| 29.8% | -13.5% | -20.1% | |
| 25.9% | -35.0% | -4.2% |
Balance sheet
| In millions of PLN | 2021 | 2022 | 2023 |
|---|---|---|---|
| Total assets | 1,289 | 1,083 | 965 |
| Cash | 340 | 223 | 217 |
| Total debt | 5 | 3 | 5 |
| Total liabilities | 143 | 74 | 106 |
| 1,144 | 1,009 | 862 | |
| 10 | 10 | 10 | |
| 33.7% | -14.9% | -0.3% | |
| 39.1% | -18.8% | -2.3% |
Cash flow
| In millions of PLN | 2021 | 2022 | 2023 |
|---|---|---|---|
| 503 | 41 | -0 | |
| 177 | 110 | 39 | |
| 326 | -69 | -39 | |
| Dividends paid | – | – | 24 |
| 332 | 0 | 16 | |
| – | – | – |
Valuation
- –
- –
- –
- 0.6×
- 1.1×
- –
- 16.1×
- -7.5%
- -3.8%
- –
Profitability
- 16.9%
- -20.1%
- -4.2%
- –
- -0.3%
- 6.2%
- –
- –
- –
- –
Growth
- −47.9%
- –
- –
- –
- −2.7%
Financial health
- -11.1×
- 0.01
- –
- -3.6×
- 7.46
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Questions about Mercator Medical
Is Mercator Medical a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Mercator Medical AI analysis
What does Mercator Medical do?
Mercator Medical manufactures and distributes disposable medical gloves and protective products. It is in Medical Instruments & Supplies.
Does Mercator Medical pay a dividend?
Yes. In 2023 it paid out PLN 23.9 million in dividends.
Is Mercator Medical stock halal?
Yes. Mercator Medical passes our halal screen: its business is permitted and its debt is 1% of its market value, under the 30% limit. How we check
How has Mercator Medical stock done over the past year?
Up 48.8% over the past twelve months, to PLN 57.00. It traded between PLN 37.45 and PLN 62.00 and is 8.1% below its high.
Who are Mercator Medical's competitors?
The largest listed companies in the same industry are Intuitive Surgical, EssilorLuxottica Société anonyme, Becton, Dickinson and and Medline. The peers table on this page compares their profit, growth and price with Mercator Medical's.
Prices: daily closes to Nov 10, 2026. Fundamentals: company reports via invest-like data.



